Details of the Drug Combinations

General Information of This Drug (ID: DMN1XVC)

Drug Name

Lutetium Lu 177 dotatate DMN1XVC

Synonyms

UNII-AE221IM3BB; Dotatate lutenium Lu-177; AE221IM3BB; Lu-DOTA-TATE; 177Lu-DOTA-octreotate; Lutetium Lu 177 Dotatate; 177Lu-DOTA-Tyr3-octreotate

Indication

Disease Entry	ICD 11	Status	REF
Neuroendocrine cancer	2B72.1	Approved	[1]
------------------------------------------------------------------------------------

Structure

3D MOL

2D MOL

List of Combinatorial Drugs (CBD) Containing This Drug

1 Clinical Trial Drug Combination(s) Consisting of This drug

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Cabozantinib + Lutetium Lu 177 dotatate	DC8UNM0	Cabozantinib	Neuroendocrine Tumors	[2]
------------------------------------------------------------------------------------

References

1	2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
2	ClinicalTrials.gov (NCT05249114) Study of Cabozantinib With Lu-177 in Patients With Somatostatin Receptor 2 Positive Neuroendocrine Tumors